ArticleInfectious diseases of poverty2023
Transmission risk of Oropouche fever across the Americas.
Article in Infectious diseases of poverty, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- (Re-)Emergence of Oropouche Virus (OROV) Infections: Systematic Review and Meta-Analysis of Observational Studies.Viruses · 2024Pooled it
- Article
- A novel mathematical model of seasonality in Oropouche virus transmission in Amazonas, Brazil.Journal of mathematical biology · 2026Article
- Dynamics and ecology of a multistage expansion of Oropouche virus in Brazil.Nature ecology & evolution · 2026Article
- Expanding mountain-type zoonotic visceral leishmaniasis in China: a multi-source data-driven investigation.The Lancet regional health. Western Pacific · 2026Article
- Oropouche Virus (OROV) Vaccine Development for Vulnerable Populations: Epidemiological Context, Challenges and Future Directions.Vaccines · 2026Review
- Viral emergence and pandemic preparedness in a One Health framework.Nature reviews. Microbiology · 2026Review
- Geospatial Mapping of Pediatric Febrile Illness in Uganda to Inform Precision Public Health Interventions.Open forum infectious diseases · 2026Article
- Oropouche Virus Infection: A Growing Global Public Health Concern.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine · 2025Article
- The emerging threat of Oropouche virus in Latin America: epidemiology, clinical manifestations, diagnosis, and management.Annals of medicine and surgery (2012) · 2025Review
- Structure-Based Identification of Natural Inhibitors Targeting the Gc Glycoprotein of Oropouche Virus: An In Silico Approach.International journal of molecular sciences · 2025Article
- ECOLOGICAL NICHE MODELING APPLICATIONS TO INFECTIOUS DISEASES.Biodiversity informatics · 2025Article
- Review
- Addressing the emerging threat of Oropouche virus: implications and public health responses for healthcare systems.Tropical diseases, travel medicine and vaccines · 2025Review
- Insights into the expansion of Oropouche virus in Brazil: epidemiological and environmental aspects.Experimental biology and medicine (Maywood, N.J.) · 2025Review
- Oropouche fever outbreak in Brazil: Key factors behind the largest epidemic in history.PloS one · 2025Article
- Oropouche virus and the urgent need for global surveillance.Nature microbiology · 2025Article
- Potential vectors associated to Oropouche virus transmission in Cuba, 2024.GigaByte (Hong Kong, China) · 2025Article
- Human outbreaks of a novel reassortant Oropouche virus in the Brazilian Amazon region.Nature medicine · 2024Article
- Spatiotemporal Epidemiology of Oropouche Fever, Brazil, 2015-2024.Emerging infectious diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundVector-borne diseases (VBDs) are important contributors to the global burden of infectious diseases due to their epidemic potential, which can result in significant population and economic impacts. Oropouche fever, caused by Oropouche virus (OROV), is an understudied zoonotic VBD febrile illness reported in Central and South America. The epidemic potential and areas of likely OROV spread remain unexplored, limiting capacities to improve epidemiological surveillance.
methodsTo better understand the capacity for spread of OROV, we developed spatial epidemiology models using human outbreaks as OROV transmission-locality data, coupled with high-resolution satellite-derived vegetation phenology. Data were integrated using hypervolume modeling to infer likely areas of OROV transmission and emergence across the Americas.
resultsModels based on one-support vector machine hypervolumes consistently predicted risk areas for OROV transmission across the tropics of Latin America despite the inclusion of different parameters such as different study areas and environmental predictors. Models estimate that up to 5 million people are at risk of exposure to OROV. Nevertheless, the limited epidemiological data available generates uncertainty in projections. For example, some outbreaks have occurred under climatic conditions outside those where most transmission events occur. The distribution models also revealed that landscape variation, expressed as vegetation loss, is linked to OROV outbreaks.
conclusionsHotspots of OROV transmission risk were detected along the tropics of South America. Vegetation loss might be a driver of Oropouche fever emergence. Modeling based on hypervolumes in spatial epidemiology might be considered an exploratory tool for analyzing data-limited emerging infectious diseases for which little understanding exists on their sylvatic cycles. OROV transmission risk maps can be used to improve surveillance, investigate OROV ecology and epidemiology, and inform early detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.